Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_assertion type Assertion NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_head.
- NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_provenance.
- NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_assertion evidence source_evidence_literature NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_provenance.
- NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_assertion SIO_000772 19074097 NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_provenance.
- NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_assertion wasDerivedFrom befree-20140225 NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_provenance.
- NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_assertion wasGeneratedBy ECO_0000203 NP708392.RAoWlDF1ASCW1sGe2R8Yufdi4_xG6xtyfIDPXzHI5dWoU130_provenance.